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Abstract— Recently, there has been great interest in developing 
Artificial Intelligence (AI) enabled computer-aided diagnostics 
solutions for the diagnosis of skin cancer. With the increasing 
incidence of skin cancers, low awareness among a growing 
population, and a lack of adequate clinical expertise and services, 
there is an immediate need for AI systems to assist clinicians in this 
domain. A large number of skin lesion datasets are available 
publicly, and researchers have developed AI solutions, 
particularly deep learning algorithms, to distinguish malignant 
skin lesions from benign lesions in different image modalities such 
as dermoscopic, clinical, and histopathology images. Despite the 
various claims of AI systems achieving higher accuracy than 
dermatologists in the classification of different skin lesions, these 
AI systems are still in the very early stages of clinical application 
in terms of being ready to aid clinicians in the diagnosis of skin 
cancers. In this review, we discuss advancements in the digital 
image-based AI solutions for the diagnosis of skin cancer, along 
with some challenges and future opportunities to improve these AI 
systems to support dermatologists and enhance their ability to 
diagnose skin cancer. 
 
Index Terms—Skin Cancer, Artificial Intelligence, Deep 
Learning, Dermatologists, Computer-aided Diagnostics, Digital 
Dermatology. 
 
I. INTRODUCTION 
According to the Skin Cancer Foundation, the global 
incidence of skin cancer continues to increase [1]. In 2019, it is 
estimated that 192,310 cases of melanoma will be diagnosed in 
the United States [2]. However, the most common forms of skin 
cancer are non-melanocytic, such as Basal Cell Carcinoma 
(BCC) and Squamous Cell Carcinoma (SCC). Non-melanoma 
skin cancer is the most commonly occurring cancer in men and 
women, with over 4.3 million cases of BCC and 1 million cases 
of SCC diagnosed each year in the United States, although these 
numbers are likely to be an underestimate [3]. Early diagnosis 
of skin cancer is a cornerstone to improving outcomes and is 
correlated with 99% overall survival (OS). However, once 
disease progresses beyond the skin, survival is poor [4], [5]. 
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In current medical practice, dermatologists examine patients 
by visual inspection with the assistance of polarized light 
magnification via dermoscopy. Medical diagnosis often 
depends on the patient’s history, ethnicity, social habits and 
exposure to the sun. Lesions of concern are biopsied in an office 
setting, submitted to the laboratory, processed as permanent 
paraffin sections, and examined as representative glass slides 
by a pathologist to render a diagnosis.  
AI-enabled computer-aided diagnostics (CAD) solutions are 
poised to revolutionize medicine and health care, especially in 
medical imaging. Medical imaging, including ultrasound, 
computed tomography (CT), and magnetic resonance imaging 
(MRI), is used extensively in clinical practice. In the 
dermatological realm, dermoscopy or, less frequently, confocal 
microscopy, allows for more detailed in vivo visualization of 
lesioned features and risk stratification [6], [7], [8], [9], [10]. In 
various studies, AI algorithms match or exceed clinician 
performance for disease detection in medical imaging [11], 
[12]. Recently, deep learning has provided various end-to-end 
solutions in the detection of abnormalities such as breast cancer, 
brain tumors, lung cancer, esophageal cancer, skin lesions, and 
foot ulcers across multiple image modalities of medical 
imaging [13], [14], [15], [16], [17]. 
Over the last decade, advances in technology have led to 
greater accessibility to advanced imaging techniques such as 
3D whole body photoimaging/scanning, dermoscopy, high-
resolution cameras, and whole-slide digital scanners that are 
used to collect high-quality skin cancer data from patients 
across the world [18], [19]. The International Skin Imaging 
Collaboration (ISIC) is a driving force that provides digital 
datasets of skin lesion images with expert annotations for 
automated CAD solutions for the diagnosis of melanoma and 
other skin cancers. A wide research interest in AI solutions for 
skin cancer diagnosis is facilitated by affordable and highspeed 
internet, computing power, and secure cloud storage to manage 
and share skin cancer datasets. These algorithms can be scalable 
to multiple devices, platforms, and operating systems, turning 
them into modern medical instruments [20]. 
The purpose of this review is to provide the reader with an 
update on the performance of artificial intelligence algorithms 
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used for the diagnosis of skin cancer across various modalities 
of skin lesion datasets, especially in terms of the comparative 
studies on the performance of AI algorithms and 
dermatologists/ dermatopathologists. We dedicated separate 
sub-sections to arrange these studies according to the types of 
imaging modality used, including clinical photographs, 
dermoscopy images, and whole-slide pathology scanning. 
Specifically, we seek to discuss the technical challenges in this 
domain and opportunities to improve the current AI solutions 
so that they can be used as a support tool for clinicians to 
enhance their efficiency in diagnosing skin cancers. 
II. ARTIFICIAL INTELLIGENCE FOR SKIN CANCER 
The major advances in this field came from the work of Esteva 
et al. [12] who used a deep learning algorithm on a combined 
skin dataset of 129,450 clinical and dermoscopic images 
consisting of 2,032 different skin lesion diseases. They 
compared the performance of a deep learning method with 21 
board-certified dermatologists for classification and 
differentiation of carcinomas versus benign seborrheic 
keratoses; and melanomas versus benign nevi. The performance 
of AI was demonstrated to be on par with dermatologists’ 
performance for skin cancer classification. Three main types of 
modalities are used for the skin lesion classification and 
diagnosis in the work described here: clinical images, 
dermoscopic images, and histopathology images. In this 
section, we start with analysis of publicly available skin lesion 
datasets, and then we provide different sub-sections dedicated 
to the artificial intelligence solution related to each type of 
imaging modality. 
A. Publicly Available Datasets for Skin Cancer 
1) ISIC Archive: The ISIC archive gallery consists of many 
clinical and dermoscopic skin lesion datasets from across the 
world, such as ISIC Challenges datasets [21], HAM10000 [22], 
and BCN20000 [23]. 
2) Interactive Atlas of Dermoscopy [24]: The Interactive Atlas 
of Dermoscopy has 1,000 clinical cases (270 melanomas, 49 
seborrheic keratoses), each with at least two images: 
dermoscopic, and close-up clinical. It is available for research 
purposes and has a fee of €250. 
3) Dermofit Image Library [25]: The Dermofit Image Library 
consists of 1,300 high-resolution images with 10 classes of skin 
lesions. There is a need for a licensing agreement with a one-
off license fee of €75, and an academic license is available. 
4) PH2 Dataset [26]: The PH2 Dataset has 200 dermoscopic 
images (40 melanoma and 160 nevi cases). It is freely available 
after signing a short online registration form. 
6) MED-NODE Dataset [27]: It consists of 170 clinical images 
(70 melanoma and 100 nevi cases). This dataset is freely 
available to download for research. 
7) Asan Dataset [28], [29]: It is a collection of 17,125 clinical 
images of 12 types of skin diseases found in Asian people. The 
Asan Test Dataset (1,276 images) is available to download for 
research. 
8) Hallym Dataset [28]: This dataset consists of 125 clinical 
images of BCC cases. 
9) SD-198 Dataset [30]: The SD-198 dataset is a clinical skin 
lesion dataset containing 6,584 clinical images of 198 skin 
diseases. This dataset was captured with digital cameras and 
mobile phones. 
10) SD-260 Dataset [31]: This dataset is a more balanced 
dataset when compared to the previous SD-198 dataset since it 
controls the class size distribution with preservation of 10–60 
images for each category. It consists of 20,600 images with 260 
skin diseases. 
11) Dermnet NZ [32]: Dermnet NZ has one of the largest and 
most diverse collections of clinical, dermoscopic and histology 
images of various skin diseases. These images can be used for 
academic research purposes. They have additional high-
resolution images for purchase. 
12) Derm7pt [33]: This dataset has around 2,000 dermoscopic 
and clinical images of skin lesions, with a 7-point check-list 
criteria. 
13) The Cancer Genome Atlas [34]: This dataset is one of the 
largest collections of pathological skin lesion slides with 793 
cases. It is publicly available for the research community to use. 
B. Artificial Intelligence in Dermoscopic Images 
Dermoscopy is the inspection/examination of skin lesions with 
a dermatoscope device consisting of a high-quality magnifying 
lens and a (polarizable) illumination system. Dermoscopic 
images are captured with high-resolution digital single-lens 
reflex (DSLR) or smartphone camera attachments. The use of 
dermoscopic images for AI algorithms is becoming a very 
popular research field since the introduction of many large 
publicly available dermoscopic datasets consisting of different 
types of benign and cancerous skin lesions, as shown in Fig. 1. 
There have been multiple AI studies on lesion diagnosis using 
dermoscopic skin lesion datasets, which are listed below. 
 
 
Fig. 1. Illustration of different types of dermoscopic skin lesions where (a) Nevi 
(b) Melanoma (c) Basal Cell Carcinoma (d) Actinic Keratosis (e) Benign 
Keratosis (f) Dermatofibroma (g) Vascular Lesion (h) Squamous Cell 
Carcinoma [22] 
 
1) Codella et al. [35] developed an ensemble of deep 
learning algorithms on the ISIC-2016 dataset and compared 
the performance of this network with 8 dermatologists for the 
classification of 100 skin lesions as benign or malignant. The 
ensemble method outperformed the average performance of 
dermatologists by achieving an accuracy of 76% and 
specificity of 62% versus 70.5% and 59% achieved by 
dermatologists. 
2) Haenssle et al. [36] trained a deep learning method 
InceptionV4 on a large dermoscopic dataset consisting of 
more than 100,000 benign lesions and melanoma images and 
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compared the performance of a deep learning method with 
58 dermatologists. On the test set of 100 cases (75 benign 
lesions and 25 melanoma cases), dermatologists had an 
average sensitivity of 86.6% and specificity of 71.3%, while 
the deep learning method achieved a sensitivity of 95% and 
specificity of 63.8%. 
3) Brinker et al. [37] compared the performance of 157 
board-certified dermatologists at 12 German university 
hospitals with a deep learning method (ResNet50) for 100 
dermoscopic images (MClass-D) consisting of 80 nevi and 
20 melanoma cases. Dermatologists achieved an overall 
sensitivity of 74.1%, and specificity of 60.0% on the 
dermoscopic dataset whereas a deep learning method 
achieved a specificity of 69.2% and a sensitivity of 84.2%. 
4) Tschandl et al. [38] used popular deep learning 
architectures known as InceptionV3 and ResNet50 on a 
combined dataset of 7,895 dermoscopic and 5,829 close-up 
lesion images for diagnosis of non-pigmented skin cancers. 
The performance is compared with 95 dermatologists 
divided into three groups based on experience. The deep 
learning algorithms achieved accuracy on par with human 
experts and exceeded the human groups with beginner and 
intermediate raters. 
   5) Maron et al. [39] compared the sensitivity and 
specificity of a deep learning method (ResNet50) with 112 
German dermatologists for multiclass classification of skin 
lesions which includes nevi, melanoma, benign keratosis, 
BCC, and SCC (also solar keratosis and intraepithelial 
carcinoma). The deep learning method outperformed 
dermatologists at a significant level (p ≤ 0.001). 
        6) Haenssle et al. [40] compared the deep learning 
architecture based on InceptionV4 (approved as medical 
device by European union) and dermatologists on a 
dermoscopic test set consists of 100 cases (60 benign and 40 
malignant lesions). This study was performed on two levels 
i.e. level I: dermoscopic image; level II: additional clinical 
close-up images, dermoscopic image, and clinical 
information. The deep learning algorithm achieved 
sensitivity and specificity score of 95% and 76.7% 
respectively, whereas, mean sensitivity and specificity of 
89% and 80.7% respectively achieved by dermatologists in 
level I. With more information in level II, the mean 
sensitivity of dermatologists increased to 94.1% whereas 
mean specificity remained same. 
        7) Tschandl et al. [41] compared the average 
performance of both AI algorithms (139 in total) participated 
in the ISIC 2018 challenge and 511 human readers on a test 
set of 1511 images. In results, the AI algorithms achieved 
more correct diagnosis than human readers. 
C. Artificial Intelligence in Clinical Images 
 
Clinical images are routinely captured of different skin lesions 
with mobile cameras for remote examination and incorporation 
into patient medical records, as shown in Fig. 2. Since clinical 
images are captured with different cameras with variable 
backgrounds, illuminance and color, these images provide 
different insights for dermoscopic images.  
     1) Yang et al. [30] performed clinical skin lesion 
diagnosis using representation inspired by the ABCD rule on 
the SD-198 dataset. They compared the performance of the 
proposed methods with deep learning methods and 
dermatologists. It achieved a score of 57.62% (accuracy) in 
comparison to the best performing deep learning method 
(ResNet), which achieved 53.35%. When compared to the 
clinicians, only senior clinicians who have considerable 
experience in skin disease achieved an average accuracy of 
83.29%. 
      2) Han et al. [28] trained a deep learning architecture 
(ResNet-152) to classify the clinical images of 12 skin 
diseases on an Asan training dataset, a MED-NODE dataset, 
and atlas site images, and tested it on an Asan testing set and 
an Edinburgh Dataset (Dermofit). The algorithm’s 
performance was on par with the team of 16 dermatologists 
on 480 randomly chosen images from the Asan test dataset 
(260 images) and the Edinburgh dataset (220 images), 
whereas the AI system outperformed dermatologists in the 
diagnosis of BCC. 
3) Fujisawa et al. [42] tested a deep learning method on 6,009 
clinical images of 14 diagnoses, including both malignant 
and benign conditions. The deep learning algorithm achieved 
a diagnostic accuracy of 76.5% which is superior to the 
performance of 13 board-certified dermatologists (59.7%) 
and nine dermatology trainees (41.7%) on a 140-image 
dataset. 
4) Brinker et al. [43] compared the performance of 145 
dermatologists and a deep learning method (ResNet50) for 
the test case of 100 clinical skin lesion images (MClass-ND) 
consisting of 80 nevi cases and 20 biopsy-verified melanoma 
cases. The dermatologists achieved an overall sensitivity of 
89.4%, a specificity of 64.4% and an AUROC of 0.769 
whereas a deep learning method achieved the same 
sensitivity and better specificity score of 69.2%. 
 
Fig. 2. Illustration of different types of clinical skin lesions where (a) Benign 
Keratosis (b) Melanoma (c) BCC (d) SCC [30] 
D. Artificial Intelligence in Histopathology Images 
The diagnosis of skin cancer is confirmed by 
dermatopathologists based on microscopic evaluation of a 
tissue biopsy. Deep learning solutions have been successful in 
the field of digital pathology with whole-slide imaging. 
Examples of histopathology images of skin lesions are shown 
in Fig. 3. These techniques are used for the classification of 
biopsy tissue specimens to diagnose the number of cancers such 
as skin, lung, and breast. In this section, we explore the deep 
learning methods used in digital histopathology specific to skin 
cancer. 
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      1) Heckler et al. [44] used a deep learning method 
(ResNet50) to compare the performance of pathologists in 
classifying melanoma and nevi. The deep learning model was 
trained on a dataset of 595 histopathology images (300 
melanoma and 295 nevi) and tested on 100 images 
(melanoma/nevi = 1:1). The total discordance with the 
histopathologist was 18% for melanoma, 20% for nevi, and 
19% for the full set of images. 
      2) Jiang et al. [45] proposed the use of a deep learning 
algorithm on smartphone-captured digital histopathology 
images (MOI) for the detection of BCC. They found that the 
performance of the algorithm on MOI and Whole Slide 
Imaging (WSI) is comparable with an AUC score of 0.95. 
They introduced a deep segmentation network for in-depth 
analysis of the hard cases to further improve the performance 
with 0.987 (AUC), 0.97 (sensitivity), 0.94 (specificity) score. 
     3. Cruz-Roa et al. [46] used a deep learning architecture to 
discriminate between BCC and normal tissue patterns on 
1,417 images from 308 Region of Interests (ROI) of skin 
histopathology images. They compared the deep learning 
method with traditional machine learning with feature 
descriptors, including the bag of features, canonical and Haar-
based wavelet transform. The deep learning architecture 
proved superior over the traditional approaches by achieving 
89.4% in F-Measure and 91.4% in balanced accuracy. 
     4) Xie et al. [47] introduced a large dataset of 2,241 
histopathological images of 1,321 patients from 2008 to 2018. 
They used two deep learning architectures, VGG19 and 
ResNet50, on the 9.95 million patches generated on 2,241 
histopathological images to test the classification of 
melanoma and nevi on different magnification scales. They 
achieved high accuracy in distinguishing melanoma from nevi 
with average F1 (0.89), Sensitivity (0.92), Specificity (0.94) 
and AUC (0.98). 
 
 
Fig. 3. Illustration of different types of histopathology images where (a) Nevi 
(b) Melanoma (c) Basal Cell Carcinoma (d) Squamous Cell Carcinoma [19] 
 
III. CHALLENGES IN ARTIFICIAL INTELLIGENCE 
 With deep learning algorithms surpassing the benchmarks of 
popular computer vision datasets in a short period, the same 
trend could be expected in the skin lesion diagnosis challenge 
as well. However, as we further explore the skin lesion 
diagnosis challenge, this task appears to be not straightforward 
like ImageNet, PASCAL-VOC, MS-COCO challenges in a 
non-medical domain [48], [49]. There are intra-class 
similarities and inter-class dissimilarities regarding color, 
texture, size, place, and appearance in the visual appearance of 
skin lesions. Deep learning algorithms generally require a 
substantial amount of diverse, balanced, and high-quality 
training data that represent each class of skin lesions to improve 
diagnostic accuracy. For skin lesion datasets of various 
modalities, there are many more issues related to the diagnosis 
of skin cancer with AI solutions as discussed below. 
A. Performance of Deep Learning and Unbalanced Datasets 
    The performance of deep learning algorithms mostly depends 
on the quality of image datasets rather than tuning the hyper-
parameters of networks, as is commonly seen in the different 
publicly available skin lesion datasets. There are generally more 
cases of benign skin lesions rather than malignant lesions. Most 
of the deep learning architectures are designed on a balanced 
dataset, such as ImageNet, which consists of 1,000 images per 
class (1000 classes) [48].  Hence, the performance of a deep 
learning algorithm usually suffers from unbalanced datasets, 
despite using tuning tricks like a penalty for false negatives 
found in minor skin lesion classes during training using custom 
loss functions. 
 
B. Curious Case of Histopathology Images/ Digital Pathology 
    The size of images in clinical and dermoscopic skin lesion 
datasets varies between 1200 × 768 and 3648 × 2736 depending 
on the camera used. Most of the deep learning algorithms are 
usually developed and validated on large datasets of non-
medical background. These deep learning algorithms have 
worked very well on clinical and dermoscopic skin lesion 
datasets by fine tuning the algorithms through transfer learning 
techniques. On the other hand, histopathological scans consist 
of millions of pixels and their dimensions are commonly larger 
than 50,000 x 50,000. Hence, there are many technical 
challenges for deep learning or AI algorithms in digital 
pathology such as lack of labeled data, infinite pattern from 
different types of tissues, high-quality feature extraction, high 
computational expenses and many more [50].  
C. Patients’ Medical History and Clinical Meta-data 
Patients’ medical history, social habits, and clinical meta-
data are considered when making a skin cancer diagnosis. It is 
very important to know the diagnostic meta-data, such as 
patient and family history of skin cancer, age, ethnicity, sex, 
general anatomic site, size and structure of the skin lesion, 
while performing a visual inspection of a suspected skin lesion 
with dermoscopy. Hence, only image-based deep learning 
algorithms used for the diagnosis of skin cancer falter on key 
aspects of patient and clinical information. It is proven in a 
previous study [36] that both ‘beginners’ and ‘skilled’ 
dermatologists’ performance is improved with the availability 
of clinical information and that they performed better than deep 
learning algorithms. Unfortunately, both patient history and 
clinical meta-data are missing in the most publicly available 
skin lesion datasets. 
D. ABCDE Rule and Time-line Datasets 
In the clinical setting, a suspicious lesion is visually 
inspected with the help of dermoscopy. The ABCDE rule is 
considered an important rule for differentiating benign moles 
(nevi) from melanoma. This includes whether the lesion is 
asymmetrical, has irregular borders, displays multiple colors, 
whether the diameter of the lesion is greater than six 
millimetres, and if there has been any evolution or change in the 
composition of the lesion. Despite the availability of 
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dermoscopic datasets of skin lesions, deep learning algorithms 
do not work the same way or look for a pattern similar to the 
ABCDE rule trusted by clinicians. It is mainly due to the 
complexity of pattern recognition for the characteristics of skin 
cancers in medical imaging. That is why, despite recent 
attempts by researchers to demystify the working of deep 
learning algorithms, such efforts are still considered as a black-
box approach, especially in medical imaging. Since there are no 
timeline dermoscopic datasets available publicly, it is not 
possible to determine the change of a lesion’s characteristics 
according to the evolution of the ABCDE rule.   
E. Biopsy is a Must 
Although, in various studies, AI solutions outperformed the 
human experts in diagnosis of skin cancer. But, even if skin 
cancer is confirmed by AI solutions with a high confidence rate, 
a biopsy and histological test must still be undertaken to 
confirm a diagnosis, similar to real clinical practice by 
dermatologists and general practitioners. The diagnostic 
accuracy of deep learning algorithms could be misleading as 
well. For example, if a testing set consists of 20 melanoma and 
80 nevi cases, and the overall diagnostic accuracy is 90% 
(100% in nevi and 50% in melanoma cases), it is dangerous for 
a deep learning algorithm to be used in this case as a means to 
deliver a diagnosis of melanoma. As misdiagnosis of a cancer 
patient by a deep learning algorithm could risk a fatality, a 
biopsy should be taken to ensure safety and confirm the 
algorithm’s diagnosis. 
F. Inter-class Similarities (Mimics of Skin Lesions) 
    A number of skin lesions can mimic skin cancer in both 
clinical and microscopic settings, which could result in 
misdiagnosis. For example, in clinical and dermoscopic images, 
seborrheic keratosis can mimic skin cancers including BCC, 
SCC, and melanoma. In histopathology images, there are many 
histologic mimics of BCC such as SCC, benign follicular 
tumors, basaloid follicular hamartoma, a tumor of follicular 
infundibulum, syringoma, and microcystic adnexal carcinoma 
[51]. Hence, deep learning algorithms, when trained on limited 
classes of skin lesions in a dataset, do not reliably distinguish 
skin cancers from their known mimics. 
G. Intra-class Dissimilarities 
   Several skin lesions have intra-class dissimilarities in terms 
of color, attribute, texture, size, site. Hence, these skin lesions 
are further categorized into many sub-categories based on 
visual appearance. For example, the color of most melanomas 
is black because of the dark pigment of melanin. But certain 
melanomas are found to be of normal skin color, reddish, and 
pinkish looking. Similarly, BCC has many subcategories, such 
as nodular BCC, superficial BCC, morphoeic BCC, 
Basosquamous BCC, and their appearance is completely 
different from each other, ranging from white to red in color as 
shown in Fig. 4. 
H. Communication Barrier between AI and Dermatologists 
    Sometimes even experts in computer vision find it hard to 
understand the decisions made by deep learning frameworks. 
For example, if there is an algorithm that is 85% accurate for 
the diagnosis of skin cancer, it is often very difficult to 
understand why the algorithm is making wrong inferences on 
the rest of the 15% of cases, and how to improve those 
decisions. These algorithms are not usually similar or 
representative of the ways in which clinicians make such 
decisions. Hence, deep learning algorithms are often deemed as 
a black box solution that does not offer clear explanation for its 
conclusion, and often they only provide an output in confidence 
probability ranging from 0 to 1 for classification of each skin 
lesion in a test set. Currently, it is not clear how dermatologists 
would interpret deep learning models’ outcomes in diagnosing 
of skin cancer 
I. Noisy Real-life Data with Heterogeneous Data Sources 
   In the current datasets of skin lesions, the dermoscopic images 
are captured with high-resolution DSLR cameras and in an 
optimal environment of lighting and distance of capture. A deep 
learning algorithm trained on these high-quality dermoscopic 
datasets, achieving a reasonable diagnostic accuracy, could 
potentially be scaled to smart-phone vision applications. When 
this model is tested on multiple smart phone captured images 
by different cameras in different lighting conditions and 
distances, the same diagnostic accuracy is hard to achieve. Deep 
learning algorithms are found to be highly sensitive to which 
camera devices are used to capture the data, and their 
performance degrades if a different type of camera device is 
used for testing. Patient-provided self-captured skin images are 
frequently of low-quality and are not suitable for digital 
dermatology [52], [53]. 
 
 
Fig. 4. Illustration of intra-class dissimilarities in BCC (a) Nodular BCC (b) 
Superficial BCC (c) Morphoeic BCC (d) Basosquamous BCC [32] 
J. Race, Ethnicity and Population 
   Most of the cases in the current skin lesion datasets belong to 
fair-skinned individuals rather than brown or dark-skinned 
persons. Although the risk of developing skin cancer is indeed 
relatively high among the fair-skinned person population, 
people with dark skin can also develop skin cancer and are 
frequently diagnosed at later stages [54]. Skin cancer represents 
4 to 5%, 2 to 4 %, and 1 to 2% of all cancers in Hispanics, 
Asians, and Blacks, respectively [55]. Hence, deep learning 
frameworks validated for the diagnosis of skin cancer in fair-
skinned people has a greater risk of misdiagnosing those with 
darker skin [56]. In a recent study, Han et al. [28] trained a deep 
learning algorithm on an Asan training dataset consisting of 
skin lesions from Asians. They reported an accuracy of 81% on 
the Asian testing set, whereas they reported an accuracy of only 
56% on the Dermofit dataset, which consists of skin lesions of 
Caucasian people. Therefore, this drop-in accuracy signifies a 
lack of transferability of the learned features of deep learning 
algorithms across datasets that contain persons of a different 
race, ethnicity, or population. 
 6 
K. Rare Skin Cancer and Other Skin Conditions 
BCC, SCC and melanoma collectively comprise 98% of all 
skin cancers. However, there are other skin cancers, including 
Merkel cell carcinoma (MCC), appendageal carcinomas, 
cutaneous lymphoma, sarcoma, kaposi sarcoma, and cutaneous 
secondaries, that are ignored by most algorithms. Beside these 
rare skin cancers, there are certain other skin conditions, such 
as ulcers, skin infections, neoplasms, and non-infectious 
granulomas, that could mimic skin lesions. If deep learning 
algorithms are trained on datasets that do not have adequate 
cases of these rare skin cancers and other mentioned skin 
conditions, there is a high risk of misdiagnosis when it is tested 
on these skin conditions. 
L. Incomplete Diagnosis Pipeline for Artificial Intelligence 
    In the clinical setting, the diagnosis of skin cancer is made by 
inspecting the skin lesion with or without dermoscopy, 
followed by confirmatory biopsy and pathological examination. 
The major issue with the current publicly available skin lesion 
datasets is that they lack complete labels related to the diagnosis 
performed by a dermatologist. Nevertheless, most of the 
classification labels for dermoscopic skin lesion images are 
determined by pathological examination. Still, these 
dermoscopic and clinical skin lesion datasets do not have 
corresponding pathological classification labels to develop a 
complete diagnosis pipeline for AI. 
IV. OPPORTUNITIES 
 AI researchers invariably claim their systems exceed the 
performance of dermatologists for the diagnosis of skin cancer. 
But this picture is far from reality, as these experiments are 
performed in closed systems with a defined set of rules. With 
the many challenges mentioned in the above section, the nature 
of these reported performance evaluations is nowhere near the 
real-life diagnosis performed by clinicians treating skin cancer. 
Often, deep learning algorithms are deemed as opaque, as they 
only learn from pixel values of imaging datasets and do not 
have any domain knowledge or perform logical inferences to 
establish the relationship between different types of skin lesions 
[56]. But, in the future, deep learning could do very well for the 
diagnosis of skin cancer with the given opportunities listed 
below. 
A. Balanced Dataset and Selection of Cases 
   A balanced dataset is critical for the good performance of 
deep learning algorithms used for classification tasks. Hence, 
balanced datasets are required with a selection of cases that 
completely represent the category of that particular skin lesion, 
and the input of experienced dermatologists could be very 
helpful for this selection. 
 
B. Computer Aided Diagnosis for Digital Pathology 
 
The evolution of whole slide imaging for digital image analysis 
and GPU clusters for computational power in recent years has 
attracted the interests of both pathologist and computer vision 
societies for developing computer-aided diagnosis in digital 
pathology. One of the most popular AI approach to tackle the 
dimensionality obstacle is to use the deep learning algorithms 
as sliding window classification and aggregates those 
classifications to infer predominant histologic patterns [15].    
 
C. Color Constancy for Illumination and Heterogenous Data 
Sources 
      In publicly available clinical and dermoscopic datasets, the 
skin lesion images are acquired with different illumination 
settings and acquisition devices which could reduce the 
performance of the AI systems. It is proven in many studies that 
color constancy algorithms such as Shades of Gray, max-RGB 
can be used to improve the performance of AI algorithms for 
the classification of multisource images [57], [58]. The example 
of Shadow of Gray algorithm as a pre-processing method to 
normalize the illumination and lighting effect on dermoscopic 
skin lesions images, as shown in Fig. 5. 
 
Fig. 5. Examples of pre-processing with a Shades of Gray algorithm. (a) 
Original images with different background colors; and (b) Pre-processed 
images with more consistent background colors. 
D. Diverse Datasets 
   Deep learning networks are often criticised for social biases 
due to most of the imaging data belonging to fair-skinned 
persons. Skin lesion datasets need to have racial diversity, i.e., 
they must add equally distributed skin lesion cases from fair-
skinned and dark-skinned people to reduce social or ethnic bias 
in deep learning models. The same concern can be extended to 
age, especially when the degree of skin aging or surrounding 
solar damage can influence the dataset and decision-making. 
 
E. Data Augmentation 
Data augmentation techniques may mitigate many limitations 
of datasets, such as unbalanced data among the classes of skin 
lesions and heterogeneous sources of data, by adding 
augmented samples with different image transformations, such 
as rotation, random crop, horizontal and vertical flip, 
translation, shear, color jitter, and colorspace. It is proven in 
many studies that data augmentation improved the diagnosis of 
skin cancer [59], [60]. In the HAM10000 dataset, [22] the skin 
lesion images were captured at different magnifications or 
angles or with different cameras, a process known as natural 
data augmentation. Notably, Goyal et al. [61] used a deep 
learning architecture called Faster R-CNN to develop an 
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algorithm to generate augmented copies similar to the natural 
data augmentation method used for other skin lesion datasets. 
  
F. Generative Adversarial Networks 
     Generative Adversarial Networks (GAN) are deep learning 
architectures that are attracting interest in the medical imaging 
community. GAN is mainly used to generate high-quality fake 
imaging data to overcome a limited dataset [62], [63], [64]. For 
skin cancer, GAN can be used to generate realistic synthetic 
skin lesion images to overcome the lack of annotated data [65]. 
The distribution of skin lesions in publicly available datasets is 
heavily skewed by each class’s prevalence among patients, and 
GAN can be used to generate imaging data for under-
represented skin lesion classes or rare classes of skin cancer, 
such as MCC, sebaceous carcinoma, or kaposi sarcoma.  
 
G. Identifying Sub-categories 
    There could be many visual intra-class dissimilarities in the 
appearance of skin lesions in terms of texture, color, and size. 
In most of the publicly available datasets, the collection of skin 
lesions belongs to each superclass rather than dividing them 
into sub-categories. Dealing with many intra-class 
dissimilarities and inter-class similarities (mimics of a skin 
lesion) in the skin lesion dataset, it is challenging for deep 
learning algorithms to classify or differentiate such lesions. As 
a possible solution to deal with this issue, sub-categories of each 
skin lesion should be treated as different classes in the dataset 
used for training deep learning algorithms. However, this will 
require a greater volume of training images and it will also be 
more challenging to translate into clinical practice. Therefore, 
subcategorization would require a certain degree of suspicion 
or a reasonable pre-test probability to adequately aid the 
clinician choosing the algorithm.  
H. Semantic Explanation of Prediction  
To assist clinicians, deep learning algorithms need to provide 
a semantic explanation rather than just a confidence score for 
the prediction of skin lesions. One possible solution could be 
for deep learning networks using longitudinal datasets to 
provide a semantic explanation of networks' prediction 
according to ABCDE criteria (asymmetry, border, color, 
diameter, evolution) or 7-point skin lesion malignancy checklist 
(pigment network, regression structures, pigmentation, vascular 
structures, streaks, dots and globules, blue whitish veil) [33]. 
 
I. Multiple Models for Diagnosis of Skin Cancer 
Rather than relying on a single AI solution for the diagnosis 
of skin cancer, multiple deep learning models can evaluate 
different features or aspects of skin lesions, submit predictions, 
and generate a final conclusion. In this regard, cloud 
computational power and storage is becoming more affordable 
and it will be possible to host multiple models to assist 
dermatologists in the diagnosis of skin cancer, around the world 
in parallel (or in synchrony). 
 
J. Combining Clinical Information and Imaging Features 
Clinical meta-data and patient history are considered 
clinically important in the diagnosis of skin cancer. This 
information can provide insight beyond the imaging features 
used by deep learning algorithms. Hence, there is a need to 
develop data fusion algorithms that can combine features 
comprised of clinical information with imaging features from 
deep learning models to provide final predictions of the 
diagnosis of skin cancer. In a recent study, Pacheco et al. [66] 
combined deep learning models (clinical images) and patient 
clinical information to achieve approximately 7% improvement 
in the balanced prediction accuracy. 
 
K. Multi-modality solution: Complete Diagnosis Pipeline 
If corresponding histopathological data for dermoscopic skin 
lesions were available in datasets, we could develop a complete 
AI solution similar to a dermatologist’s diagnosis pipeline. In 
the first step, an AI solution is used to classify dermoscopic skin 
lesions, with a deep learning algorithm trained on the 
dermoscopic dataset. For suspected cases, the deep learning 
algorithm can be developed on a pathological dataset to 
determine whether the lesion is cancerous or not.   
 
L. Rigorous Clinical Validation 
It is a well-known fact, for both clinicians and AI researchers, 
that mistakes can inform future decision-making. Since we 
cannot afford misdiagnosis by technology, it is better to keep 
AI solutions in the background for rigorous validation of noisy 
data coming from real patients and for improving the 
predictions of these technological systems to date, until they are 
finally validated to provide useful insights into the diagnosis of 
skin cancer and assist clinicians either in hospital and remote 
settings.     
V. CONCLUSION 
Research involving AI is making encouraging progress in the 
diagnosis of skin cancer. Despite the various claims of deep 
learning algorithms surpassing clinicians’ performance in the 
diagnosis of skin cancer, there are far more challenges faced by 
these algorithms to become a complete diagnostic system. 
Because such experiments are performed in controlled settings, 
algorithms are never tested in the real-life diagnosis of skin 
cancer patients. The real-world diagnosis process requires 
taking into account a patient’s ethnicity, skin, hair and eye 
color, occupation, illness, medicines, existing sun damage, the 
number of nevi, and lifestyle habits (such as sun exposure, 
smoking, and alcohol intake), clinical history, the respond to 
previous treatments, and other information from the patient’s 
medical records. However, current deep learning models 
predominantly rely on only patients’ imaging data. Moreover, 
such systems often risk a misdiagnosis whenever they are 
applied to skin lesions or conditions that are not present in the 
training dataset. This paper further explores opportunities to 
build robust algorithms to assist clinicians in the diagnosis of 
skin cancer. Computer vision and dermatologist societies need 
to work together to improve current AI solutions and enhance 
the diagnostic accuracy of methods used for the diagnosis of 
skin cancer. AI has the potential to deliver a paradigm shift in 
the diagnosis of skin cancer, and thus a cost-effective, remotely 
accessible, and accurate healthcare solution. 
 
Search strategy and selection criteria 
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We used Google Scholar and PubMed to find relevant 
manuscripts. We restricted our search to papers published in 
English between Jan 1, 2012, and Jan 11, 2020. We used the 
following terms in different combinations: “skin cancer”, “skin 
lesions", “rare skin cancer”, “deep learning”, “artificial 
intelligence”, “dermatologists”, “clinical images”, 
“dermoscopic”, “histopathology”, “social bias”, “artificial 
intelligence and skin cancer”, “skin cancer and deep learning”, 
“dermatologists and deep learning”, “skin cancer datasets”, 
“lesion diagnosis and deep learning”, “clinical information, 
deep learning and skin cancer”, “data augmentation and skin 
cancer”, “GAN and skin cancer”. 
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